Posters
« Back
The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
EP28949
The MODEL-AD consortium preclinical testing pipeline: pharmacokinetics and pharmacodynamics of prophylactic treatment with levetiracetam on the 5XFAD mouse model of Alzheimer’s Disease
Submitted on 14 Aug 2018

SJ Sukoff Rizzo1, SK Quinney2, KD Onos1, KJ Keezer1, DR Jones2, AR Masters2, IF Metzger2, JA Meyer2, J Peters2, SC Persohn2, BR McCarthy2, AA Riley2, M Sasner1, G Howell1, H Williams1, AJ Oblak2, BL Lamb2, and PR Territo2
1The Jackson Laboratory, Bar Harbor, Maine USA; 2Indiana University School of Medicine, Indianapolis, Indiana USA
This poster was presented at AAIC 2018
Poster Views: 294
View poster »
Poster Abstract
The preclinical testing core (PTC) of the Model Organism Development for Late Onset Alzheimer’s Disease (MODEL-AD) consortium has established a streamlined preclinical drug testing strategy with go/no-go decision points that allow critical and unbiased assessments of potential therapeutic agents. The goals of the PTC are to develop a testing strategy that maximizes the therapeutic potential of all drug candidates by initiating the dosing strategy prior to the onset of disease relevant biomarker readouts.
The PTC strategy includes a primary screen to determine: 1) drug formulation; 2) drug stability; and 3) in vivo pharmacokinetics and target tissue concentrations in models at disease-relevant ages. A secondary screen evaluates target engagement and disease modifying activity utilizing non-invasive PET/MRI as a pharmacodynamic (PD) readout matched to known disease pathology in the model. Compounds demonstrating positive PD effects in the secondary screen are further interrogated via a tertiary screen of functional assays that assess the compounds ability to normalize a disease-related phenotype in cognition and neurophysiological tests. For the present studies, we selected levetiracetam (LEV), a compound currently in clinical trials for the treatment of cognitive impairment associated with AD, for testing in 5XFAD mice.
Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


Clinical Trial Summaries: Readability to Effectively Inform Patients
Autumn Sky Watson

Strategies for High-Titer Protein Expression Using the ExpiCHO and Expi293 Transient Expression Systems
Chao Yan Liu, Jian Liu, Wanhua Yan, Kyle Williston, Katy Irvin, Henry Chou, Jonathan Zmuda

A Chemically-Defined Baculovirus-Based Expression System for Enhanced Protein Production in Sf9 Cells
Maya Yovcheva, Sara Barnes, Kenneth Thompson, Melissa Cross, Katy Irvin, Mintu Desai, Natasha Lucki, Henry Chiou, Jonathan Zmuda

A New Method for the Reliable Detection of 13C Multiplets of Fluorine Containing Compounds
Dimitris Argyropoulos, Rostislav Pol, Vladimir Mikhailenko, and Sergey Golotvin

Development of an in vitro Model System for Newcastle Disease Virus Persistence in Bladder Cancer Cells
Ahmad U1,, Chan SC2, Chau DM1, Chia SL5, Abdullah S1,3, Yusoff K5 & Veerakumarasivam A1,4*